SCHEMBL2291001

SCHEMBL2291001

Cc1ccc(Oc2ccc(C(=O)Nc3ccccc3C(=O)O)cc2)cc1C

nearest known ligand 0.68

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
NR1H4 Q96RI1 1/20 0.62
MEN1 O00255 2/20 0.62
NPC1 O15118 2/20 0.62
KMT2A Q03164 2/20 0.62
RAB9A P51151 1/20 0.62
SMN1; SMN2 Q16637 1/20 0.62
TDP1 Q9NUW8 1/20 0.60
SERPINE1 P05121 1/20 0.59
DHODH Q02127 1/20 0.57
PLK1 P53350 1/20 0.56
CHEK1 O14757 1/20 0.55
PIM1 P11309 1/20 0.55
MAPK8 P45983 1/20 0.55
CLK4 Q9HAZ1 1/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2269896 0.89 TDP1 (0.58) NR1H4MEN1NPC1KMT2ARAB9A
SCHEMBL30466712 0.88 MEN1 (0.72) MEN1NPC1KMT2ARAB9ASMN1; SMN2
SCHEMBL2025586 0.88 MEN1 (0.72) MEN1NPC1KMT2ARAB9ASMN1; SMN2
SCHEMBL2289345 0.87 MAPK1 (0.57) NR1H4MEN1NPC1KMT2ARAB9A
SCHEMBL2291746 0.87 MEN1 (0.67) NR1H4MEN1NPC1KMT2ARAB9A
SCHEMBL2292518 0.87 SERPINE1 (0.71) MEN1NPC1KMT2ARAB9ASMN1; SMN2
SCHEMBL2273533 0.86 TDP1 (0.69) NR1H4MEN1KMT2ARAB9ATDP1
SCHEMBL2288393 0.86 MAPK1 (0.67) NR1H4MEN1NPC1KMT2ARAB9A
SCHEMBL2330281 0.85 MEN1 (0.69) NR1H4MEN1NPC1KMT2ARAB9A
SCHEMBL6408811 0.85 MEN1 (0.64) MEN1NPC1KMT2ARAB9ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7989657-B2 Anthranilic acid derivatives HOFFMANN-LA ROCHE INC. (US) 2011-08-02 US claimed
US-20090247637-A1 Novel Anthranilic Acid Derivatives DEHMLOW HENRIETTA 2009-10-01 US claimed
JP-2008546661-A 2008-12-25 JP claimed
EP-1896396-A1 ANTHRANILIC ACID DERIVATIVES F.HOFFMANN-LA ROCHE AG (CH) 2008-03-12 EP claimed
WO-2006134040-A1 ANTHRANILIC ACID DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2006-12-21 WO claimed
US-20060281810-A1 Novel anthranilic acid derivatives HOFFMANN-LA ROCHE INC. 2006-12-14 US claimed
US-7989657-B2 Anthranilic acid derivatives HOFFMANN-LA ROCHE INC. (US) 2011-08-02 US disclosed
US-20090247637-A1 Novel Anthranilic Acid Derivatives DEHMLOW HENRIETTA 2009-10-01 US disclosed
EP-1896396-A1 ANTHRANILIC ACID DERIVATIVES F.HOFFMANN-LA ROCHE AG (CH) 2008-03-12 EP disclosed
WO-2006134040-A1 ANTHRANILIC ACID DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2006-12-21 WO disclosed
US-20060281810-A1 Novel anthranilic acid derivatives HOFFMANN-LA ROCHE INC. 2006-12-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060281810-A1 Novel anthranilic acid derivatives GPR84, HCAR1, GPR88 NR1H4 56/4885MEN1 1329/4885NPC1 3594/4885
US-20090247637-A1 Novel Anthranilic Acid Derivatives GPR84, GPR88, HCAR1 NR1H4 50/4885MEN1 1049/4885NPC1 3210/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.